Re: Schlenker et  al.: Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. (Ophthalmology. 2017;124:1579-1588)

We read with interest the paper by Schlenker et  al.1 The authors state that the results with the Xen implant (Allergan, Parsippany-Troy Hills, NJ) with mitomycin C (MMC) are very similar to those of trabeculectomy with MMC in terms of both safety and efficacy. Based on these data, they suggest that the Xen implant is a reasonable alternative to trabeculectomy. When comparing the 2 groups in this paper, this finding does indeed seem to be the case. However, we think it is reasonable to point out that results from the trabeculectomy group are considerably worse than those from other real-world studies.

Source: Ophthalmology - March 19, 2018 Category: Opthalmology Authors: James Kirwan, Alastair Lockwood, Peter Shah, David Broadway, Andrew McNaught, Anthony King Tags: Correspondence Source Type: research